Vasodilators Market Report 2026

The vasodilators market size has grown strongly in recent years. It will grow from $6.76 billion in 2025 to $7.16 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to increasing cases of hypertension, established clinical use of nitrates, growth in hospital infrastructure, rising incidence of heart failure, widespread availability of oral vasodilators.

The vasodilators market size is expected to see strong growth in the next few years. It will grow to $8.86 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to aging global population, rising burden of lifestyle-related diseases, expansion of specialty cardiac centers, increased focus on early diagnosis, growing access to cardiovascular medications. Major trends in the forecast period include rising prevalence of cardiovascular diseases, growing use of combination drug therapies, increased adoption of generic vasodilators, expansion of hospital-based cardiovascular care, higher demand for long-term hypertension management.

The increasing incidence of cardiovascular diseases is anticipated to drive the growth of the vasodilators market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. The growing prevalence of these conditions is largely fueled by rising obesity rates, which continue to climb due to poor dietary habits and sedentary lifestyles. The vasodilators market aids in the management of cardiovascular diseases by relaxing blood vessels, reducing blood pressure, and enhancing overall blood circulation. For example, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, up 4% from 224.4 per 100,000 in 2023. Consequently, the increasing prevalence of cardiovascular diseases is contributing to the growth of the vasodilators market.

The rising prevalence of sedentary lifestyles is anticipated to drive the growth of the vasodilators market in the coming years. A sedentary lifestyle is characterized by limited physical activity and extended periods of sitting or lying down, often linked to minimal exercise or movement. Its increase is largely attributed to modern conveniences such as technology, transportation, and desk-bound occupations, which encourage prolonged inactivity. Vasodilators are utilized in such lifestyles to enhance blood circulation and lower hypertension, thereby reducing cardiovascular risks. For example, in July 2023, the Office for National Statistics, a UK government department, reported that over 86.5% of adults in Great Britain had implemented lifestyle changes to address environmental concerns, based on survey data collected from May to June 2023. Consequently, the growing prevalence of sedentary lifestyles is contributing to the expansion of the vasodilators market.

Major companies operating in the vasodilators market are increasingly concentrating on developing innovative therapies, such as inhaled soluble guanylate cyclase (sGC) activators, to enhance pulmonary blood flow and manage cardiovascular conditions more effectively. Inhaled soluble guanylate cyclase (sGC) activators are medications that, when inhaled, stimulate the sGC enzyme to relax blood vessels and improve circulation, particularly in the lungs. For example, in September 2024, Roivant Sciences Ltd., a US-based biopharmaceutical and healthcare technology company, introduced mosliciguat, a once-daily, inhaled sGC activator delivered via a dry powder inhaler (DPI), developed by its subsidiary Pulmovant. Mosliciguat is designed for lung-targeted delivery, activates sGC independent of heme and NO (potentially preserving its function even under oxidative stress), and demonstrated mean‑max reductions in pulmonary vascular resistance (PVR) of up to ~38% in pulmonary hypertension patients during a Phase 1b “ATMOS” study. It was generally well tolerated, with low incidence of adverse events, and its pharmacokinetic profile supports once-daily inhalation with a long half-life and minimal systemic exposure. Pulmovant has commenced a global Phase 2 “PHocus” trial in approximately 120 patients with PH‑ILD to further evaluate its safety and efficacy.

Major companies operating in the vasodilators market are Pfizer Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Abbott Laboratories, AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Amgen Inc., Gilead Sciences Inc., Biogen, Sun Pharmaceutical Industries Limited.

North America was the largest region in the vasodilators market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vasodilators market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vasodilators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the vasodilators market by increasing the cost of imported active pharmaceutical ingredients and formulation intermediates used in drug manufacturing. These effects are most evident in injectable and parenteral vasodilator segments, particularly in regions that are highly dependent on api imports. Rising tariff related input costs have influenced drug pricing structures and public and private procurement strategies. In some markets, this has led to tighter hospital purchasing controls and delayed sourcing decisions. However, tariffs are promoting domestic api production, encouraging local formulation investments, and strengthening regional pharmaceutical supply chains over time.

The vasodilators market research report is one of a series of new reports that provides vasodilators market statistics, including vasodilators industry global market size, regional shares, competitors with a vasodilators market share, detailed vasodilators market segments, market trends and opportunities, and any further data you may need to thrive in the vasodilators industry. This vasodilators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vasodilators are drugs that expand blood vessels by relaxing the smooth muscle cells in the vessel walls, particularly in major arteries and veins. They are prescribed to manage conditions like hypertension (high blood pressure), angina (chest discomfort), and heart failure by decreasing the heart’s workload and enhancing blood flow.

The main categories of vasodilators include arterial dilators, venous dilators, and mixed dilators. Arterial dilators are medications that primarily expand the arteries, improving blood flow from the heart to the rest of the body. These drugs include nitroglycerin, alprostadil, minoxidil, sorbitrate, among others, and are indicated for conditions such as hypertension, angina, heart failure, and more. They can be administered through various routes, including oral and parenteral methods, and are utilized by different end users, such as hospitals, homecare services, specialty centers, and others.

The vasodilators market consists of sales of tablets, capsules, injectable solutions, transdermal patches, oral solutions, sublingual tablets, intravenous infusions, topical creams, and gels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.